Home › Stargardt Disease
Stargardt Disease clinical trials recruiting in the U.S.
17 studies for Stargardt Disease are recruiting participants at sites across the United States.
Cities with the most studies
- Dallas, TX9 studies
- Boston, MA5 studies
- Cincinnati, OH4 studies
- Phoenix, AZ4 studies
- Houston, TX4 studies
- Ann Arbor, MI4 studies
- Gainesville, FL4 studies
- Portland, OR4 studies
- Miami, FL4 studies
- Baltimore, MD3 studies
- Aurora, CO3 studies
- Pittsburgh, PA3 studies
By state
- Arizona4 studies
- California9 studies
- Colorado3 studies
- Florida8 studies
- Maryland5 studies
- Massachusetts5 studies
- Michigan5 studies
- Ohio5 studies
- Oregon4 studies
- Pennsylvania3 studies
- Texas10 studies
Recently updated studies
Study of ALK-001 on the Progression of Stargardt Disease
RecruitingPhase 3
Ages 8 to 45 · All sexes · Updated Sep 18, 2026 · NCT07419334The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT06319872A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions
RecruitingPhase 1
Ages 6 and older · All sexes · Updated Sep 16, 2026 · NCT07734064Rod and Cone Mediated Function in Retinal Disease
RecruitingObservational studyHealthy volunteers welcome
Ages 5 to 100 · All sexes · Updated Aug 31, 2026 · NCT02617966A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
RecruitingObservational study
Ages 6 and older · All sexes · Updated Aug 25, 2026 · NCT07425574Phase 1 Study of C.001 in Retinal Degeneration
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT07594236A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)
RecruitingPhase 1/2
Ages 8 to 55 · All sexes · Updated Jul 30, 2026 · NCT07161544Stem Cell Ophthalmology Treatment Study II
Recruiting
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT03011541Inherited Retinal Degenerative Disease Registry
RecruitingObservational studyHealthy volunteers welcome
All ages · All sexes · Updated May 19, 2026 · NCT02435940Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease
RecruitingPhase 1/2
Ages 16 and older · All sexes · Updated Apr 15, 2026 · NCT07439887Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)
RecruitingObservational study
Ages 18 and older · All sexes · Updated Mar 31, 2026 · NCT07502664Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)
RecruitingObservational study
Ages 5 and older · All sexes · Updated Mar 11, 2026 · NCT06445322Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Dec 2, 2025 · NCT06467344An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
RecruitingObservational study
Ages 12 to 65 · All sexes · Updated Sep 19, 2025 · NCT06435000A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
RecruitingPhase 1/2
Ages 12 to 65 · All sexes · Updated Apr 29, 2025 · NCT06942572A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Mar 24, 2025 · NCT06805474Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jan 8, 2025 · NCT06375239From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.